Saturday 17 October 2026
Export CARM’s income statement to Excel — free account
Carisma Therapeutics Inc.
CARM Healthcare Biotechnology
Carisma Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $19.6 million, up 31.6% from fiscal 2023. In the quarter to September 2025, revenue grew 392.0%, EPS grew 445.2% and free cash flow grew 114.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.00
0.02
−100.00%
Follow CARM
| Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 24.88 |
Piotroski F-Score |
4 | 4 | 2 | — | — | — | — | 2 | 7 |
P/S ratio |
0.89 | 6.38 | 2.77 | 3.93 | 3.88 | — | — | 0.72 | 1.40 |
Altman Z-Score |
(19.65) | (5.13) | (4.85) | 0.41 | (2.91) | — | — | (3.73) | (0.66) |
Altman Z″-Score (non-manufacturers) |
(45.25) | (10.41) | (9.90) | 3.38 | (7.22) | — | — | (8.00) | (1.67) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 14.66 |
P/Operating CF |
(2.08) | (5.91) | (1.59) | (11.79) | (18.76) | — | — | (5.98) | (7.49) |
P/B ratio |
0.00 | 3.59 | 0.00 | 0.87 | 0.00 | — | — | 1.20 | 1.08 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 1.03 | 0.00 | — | — | 0.00 | 0.00 |
EV/Sales |
(0.02) | 1.20 | 1.00 | (0.37) | 2.54 | — | — | 0.24 | 0.56 |
EV/EBITDA |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 5.50 |
EV/Operating CF |
0.01 | (0.22) | (1.91) | 0.20 | (3.38) | — | — | (0.40) | 6.59 |
EV/FCF |
0.01 | (0.22) | (1.00) | 0.20 | (3.37) | — | — | (0.40) | 5.85 |
Quick Ratio |
1.12 | 4.88 | 2.64 | 16.18 | 3.07 | 5.65 | 8.25 | 3.11 | 6.37 |
Current Ratio |
1.48 | 5.06 | 2.78 | 17.77 | 3.48 | 6.39 | 8.47 | 3.17 | 6.51 |
Net Debt/EBITDA |
0.30 | 0.91 | 0.34 | (7.00) | 2.64 | 0.44 | 1.47 | 0.51 | (8.33) |
Debt/Assets |
0.07% | 0.37% | 47.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.01 | (0.24) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.33 | 0.18 | 0.06 | 0.15 | 0.09 | 0.00 | 0.00 | 0.00 | 0.43 |
Operating CF/Net income |
0.99 | 0.93 | 0.08 | 204.99 | 1.37 | 0.35 | 0.68 | 0.61 | 1.34 |
Capex/Depreciation |
(0.04) | (0.27) | (1.05) | 0.00 | (0.07) | (0.62) | (0.01) | 0.34 | 1.83 |
Interest Coverage |
— | — | (30.29) | — | — | — | — | — | 11.60 |
| 8,783.88% | 149.61% | (421.67%) | (0.41%) | 125.50% | (1,228.08%) | (108.27%) | (102.38%) | 6.56% | |
| (100.78%) | (107.45%) | (39.13%) | (0.18%) | (19.01%) | (95.16%) | (36.10%) | (32.40%) | 2.68% | |
ROIC |
0.00% | 0.00% | 0.00% | (58.88%) | 0.00% | 0.00% | 0.00% | (545.15%) | 13.43% |
Return on Tangible Assets |
(497.55%) | (121.80%) | (140.59%) | (0.17%) | (50.16%) | (232.85%) | (73.30%) | (269.21%) | 8.31% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 336.80 | 0.00 | — | — | 0.00 | 0.00 |
Research and Development Expense of Revenue |
303.96% | 496.85% | 575.74% | 95.36% | 259.80% | 0.00% | 0.00% | 2,943.53% | 44.96% |
Selling, General and Administrative Expense of Revenue |
112.76% | 197.90% | 95.36% | 110.73% | 127.29% | 0.00% | 0.00% | 1,898.82% | 49.15% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.12 | 0.48 | 0.52 | 0.53 | 0.79 | 0.74 |
Share Based Compensation of Revenue |
18.59% | 15.52% | 2.80% | 19.38% | 15.64% | 0.00% | 0.00% | 324.94% | 13.39% |
Graham Net Nets |
(1.98) | 0.18 | (5.89) | 0.92 | (0.43) | — | — | (1.94) | (0.94) |
Graham Number |
4.70 | 0.00 | 208.33 | 0.00 | 12.71 | — | — | 0.00 | 36.34 |
Earnings Yield |
(347.88%) | (122.18%) | (225.13%) | (12.27%) | (17.04%) | — | — | (137.35%) | 4.02% |
Free Cash Flow Yield |
(344.83%) | (86.45%) | (35.95%) | (46.36%) | (19.41%) | — | — | (81.54%) | 6.82% |
Revenue per Share |
0.47 | 0.45 | 4.62 | 2.91 | 1.90 | 0.00 | 0.00 | 0.33 | 28.44 |
Operating CF per Share |
(1.45) | (2.42) | (2.40) | (7.56) | (5.22) | (8.25) | (7.39) | (13.61) | 2.41 |
Capex per Share |
0.00 | (0.03) | (2.19) | 0.00 | 0.00 | (0.03) | 0.00 | 0.08 | 0.31 |
Free Cash Flow per Share |
(1.45) | (2.46) | (4.59) | (7.56) | (5.22) | (8.28) | (7.39) | (13.53) | 2.72 |
Cash per Share |
0.43 | 2.31 | 24.43 | 17.84 | 9.37 | 10.58 | 16.32 | 11.25 | 24.04 |
Shareholders Equity per Share |
(0.67) | 0.79 | (67.04) | 18.84 | (1.56) | (5.87) | 14.31 | 13.82 | 36.69 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.67) | 0.79 | (67.04) | 18.84 | (1.56) | (5.87) | 14.31 | 13.82 | 36.69 |
Free Cash Flow |
(60.04) | (82.31) | (9.78) | (68.88) | (30.84) | (37.66) | (22.83) | (17.67) | 2.86 |
Working Capital |
7.77 | 64.56 | 34.92 | 194.04 | 44.82 | 45.93 | 45.64 | 10.26 | 21.95 |
Capital Expenditures |
(0.12) | (1.13) | (4.66) | 0.00 | (0.01) | (0.14) | 0.00 | 0.10 | 0.33 |
Net Current Asset Value |
(34.54) | 17.45 | (160.23) | 136.57 | (69.18) | (86.62) | (15.60) | (42.08) | (39.49) |
EV/EBIT |
0.01 | 0.00 | 0.00 | 1.63 | 0.00 | — | — | 0.00 | 5.84 |
Capex to Sales |
0.01 | 0.08 | 0.47 | 0.00 | 0.00 | 0.00 | 0.00 | (0.23) | (0.01) |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 14.64 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.76 | 0.61 | 0.51 | 739.19 | 0.99 | 0.92 | 0.65 | 0.55 | 0.22 |
Cash ROIC |
601.60% | (78.79%) | 17.43% | (20.60%) | (66.82%) | (175.79%) | (24.13%) | (54.00%) | 4.47% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.78 | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — |
Average Receivables |
— | — | 12.66 | — | — | — | — | — | — |
Average Payables |
3.01 | 2.83 | 2.29 | 2.98 | 2.50 | 1.63 | 1.14 | 1.29 | 1.46 |
Average Assets |
60.01 | 80.85 | 156.45 | 181.79 | 118.59 | 112.96 | 93.33 | 89.60 | 70.46 |
Average Common Equity |
(0.69) | (58.07) | 14.52 | 81.24 | (17.96) | 8.75 | 31.12 | 28.36 | 28.81 |
Columns are period end dates